Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine

Area of Science:

• Psychiatry
• Clinical Pharmacology
• Neuroscience

Background:

• Major depressive disorder (MDD) is a prevalent mental health condition associated with increased suicide risk.
• Antidepressant medications are a cornerstone of MDD treatment, but their safety profile, particularly regarding suicidality, requires ongoing evaluation.
• Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is prescribed for MDD, necessitating a thorough risk assessment for suicidal ideation and behavior.

Purpose of the Study:

• To retrospectively assess the risk of increased suicidal thoughts and behavior (suicidality) associated with desvenlafaxine treatment in adult patients diagnosed with MDD.
• To compare the incidence of suicidality-related adverse events between patients receiving desvenlafaxine and those receiving a placebo.
• To analyze the occurrence of emerging or worsening suicidality using the Hamilton Rating Scale for Depression suicide item.

Main Methods:

• Analysis of data from 9 double-blind, 8-week studies involving outpatients with MDD.
• Random assignment of patients to desvenlafaxine (n=1834) or placebo (n=1116).
• Identification and classification of suicidality-related adverse events using the Columbia Classification Algorithm of Suicide Assessment and the 17-item Hamilton Rating Scale for Depression suicide item.

Main Results:

• 17 (0.93%) patients on desvenlafaxine and 8 (0.72%) on placebo reported possible suicidality-related adverse events, with events evenly distributed between groups.
• No significant differences were observed in the risk for any class of suicide-related events, including completed suicide or suicide attempts, between desvenlafaxine and placebo groups.
• The odds of emergence or worsening of suicidality did not differ significantly between the treatment groups.

Conclusions:

• Short-term trials of desvenlafaxine in adult MDD patients did not reveal evidence of an increased signal for suicidality.
• While suicidal events were rare, a definitive conclusion regarding an increased risk cannot be made due to the low event rate.
• Further long-term studies may be warranted to fully elucidate the risk profile of desvenlafaxine concerning suicidality.